Core Viewpoint - The stock of Jimin Health Management Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over two consecutive trading days, prompting a risk warning to investors [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price increased by 53.78% from August 13 to August 19, 2025, with significant deviations from the market and sector trends [2][7]. - The stock's closing price deviation reached a cumulative value of 20% on August 18 and 19, 2025, qualifying as an abnormal trading situation under the Shanghai Stock Exchange rules [3][4]. Group 2: Company Verification and Confirmation - The company conducted a self-examination and confirmed that there were no significant changes in its main business or external operating environment, and no undisclosed major matters exist [4][5]. - The company received written confirmation from its controlling shareholder and actual controller, stating that there are no undisclosed major asset restructurings, share issuances, or significant transactions [4][5]. Group 3: Financial Performance Risks - The company reported a net loss of 59.71 million yuan for the fiscal year 2024 and anticipates a net loss between 55 million yuan and 46 million yuan for the first half of 2025, indicating a decline compared to the previous year [2][7]. - The recent stock price increase is not aligned with the company's fundamental performance, suggesting a risk of short-term price correction [2][7].

重要内容提示： ● 公司股票于2025年8月15日、8月18日、8月19日连续3个交易日内日收盘价格涨幅偏离值累计超过 20%，属于《上海证券交易所交易规则》规定的股票交易异常波动情形。 ● 经公司自查并向公司控股股东征询确认，截至本公告披露日，除已披露的信息外，不存在影响公司股 票交易异常波动的应披露而未披露的重大信息。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600737 证券简称：中粮糖业 公告编号：2025-021 中粮糖业控股股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 ● 根据公司2025年7月15日于上海证券交易所网站（www.sse.com.cn）披露的《公司2025年半年度业绩 预告》（公告编号：2025-017），预计2025年半年度归属于上市公司股东的净利润为42,384万元到 49,076万元，与上年同期（法定披露数据）相比，将减少37,174万元到43,866万元，同比减少43.10%到 50.86%，敬请广大投资者注意业绩波动风险。 一 ...

Core Viewpoint - The stock of Founder Technology Group Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days in August 2025 [2][3]. Group 1: Stock Trading Abnormality - The company's stock (stock code: 600601) had a cumulative closing price increase of 20% on August 15, 18, and 19, 2025, which qualifies as an abnormal trading fluctuation according to the Shanghai Stock Exchange trading rules [2][3]. - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal and external operating environment [4]. Group 2: Major Events - The company plans to implement a specific issuance of A-shares for the year 2025, which was approved at the first extraordinary general meeting of shareholders on June 27, 2025. This issuance is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [5][6]. - As of the announcement date, the company and its controlling shareholders have no undisclosed major events that could affect the stock, such as asset restructuring or significant transactions [5][6]. Group 3: Market Sentiment and Other Information - The company has not identified any media reports or market rumors that could impact its stock price, nor is it involved in any trending concepts [6]. - During the period of abnormal stock trading, the company's directors, supervisors, senior management, and controlling shareholders did not engage in buying or selling the company's stock [7]. - The company disclosed a share reduction plan by a shareholder, intending to reduce up to 94,511,991 shares, with a reduction period from August 7 to November 6, 2025 [7].

Group 1 - The company experienced a significant stock price fluctuation, with a cumulative deviation of 35.11% over two consecutive trading days on August 18 and 19, 2025, indicating abnormal trading activity [1] - The company's board of directors conducted inquiries with major stakeholders, including the controlling shareholder and senior management, confirming no undisclosed significant information affecting stock trading [1][2] - The company has not disclosed any major matters related to its pre-restructuring process that have not been previously reported, ensuring compliance with relevant regulations [2][3] Group 2 - The company is currently undergoing a pre-restructuring process, which is a preliminary step before formal restructuring, and the outcome remains uncertain [3] - If the restructuring is successful, it could improve the company's financial structure and sustainability; however, failure could lead to bankruptcy and delisting risks [3]

Core Viewpoint - The company announced that its stock experienced abnormal trading fluctuations, with a cumulative closing price increase deviation exceeding 20% over three consecutive trading days in August 2025, despite normal operational conditions and no significant changes in the internal or external environment [1] Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.489 billion yuan, representing a year-on-year decline of 18.86% [1] - The net profit attributable to shareholders of the listed company was 257 million yuan, a decrease of 42.90% compared to the same period last year [1] Stock Trading Activity - The company's controlling shareholder and actual controller did not engage in any buying or selling of the company's stock during this period [1] - The company confirmed that there are no undisclosed significant matters that should have been disclosed [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 针对公司股票交易异常波动，公司对有关事项进行了核查，并函询了公司控股股东及实际控制人，现将 有关情况说明如下： 1、公司前期披露包括但不限于2025年半年度报告的信息不存在需要更正、补充之处； 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息； 3、近期公司经营情况正常，内外部经营环境未发生重大变化； 一、股票交易异常波动的情况 巨力索具股份有限公司（以下简称"公司"）股票（证券代码：002342，证券简称：巨力索具）连续三个 交易日（8月14日、8月15日、8月18日）累计偏离22.53%，已达到异常波动标准。根据深圳证券交易所 的相关规定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 5、公司控股股东、实际控制人在公司股票异常波动期间不存在买卖公司股票的情形。 三、是否存在应披露而未披露信息的说明 4、公司、控股股东及实际控制人不存在关于本公司的应披露而未披露的重大事项，或处于筹划阶段的 重大事项； 本公司董事 ...

Core Viewpoint - The company, JuLi Rigging, announced that its stock experienced an abnormal fluctuation, deviating by 22.53% over three trading days, which meets the criteria for significant volatility [1] Group 1: Stock Performance - The stock deviated by 22.53% over three trading days: August 14, August 15, and August 18 [1] - The company confirmed that there are no undisclosed significant matters affecting the stock price [1] Group 2: Company Operations - The company stated that its operational status is normal and there have been no significant changes in the internal or external environment [1] - The company plans to invest 100 million RMB to establish a wholly-owned subsidiary, JuLi Rigging Ocean Technology (Tianjin) Co., Ltd., by August 14, 2025 [1] Group 3: Investment Risks - There is a noted risk of profit uncertainty or not meeting expectations regarding the new subsidiary [1]

Core Viewpoint - The stock price of Chunzhong Technology has surged significantly, reaching a historical high of 126.69 CNY per share, with a monthly increase of 300% [1][4]. Group 1: Stock Performance - As of August 18, Chunzhong Technology's stock price increased by 10% in one day, marking a continuous rise for nearly a month [1]. - The company has issued five announcements regarding severe abnormal stock trading fluctuations in August, with a cumulative price deviation of 20% over three consecutive trading days [4]. Group 2: Company Fundamentals - Chunzhong Technology is a professional audio and video system solution provider, but it is expected to report a net loss of between -41 million CNY and -38.4 million CNY for the first half of 2025 [6]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -44.5 million CNY and -41.55 million CNY [6]. Group 3: Market Rumors - There are rumors circulating about a potential partnership between Chunzhong Technology and Nvidia, which have been denied by the company's management, stating that they are preparing to report the rumors [1].

Core Viewpoint - The company, 华胜天成, announced that its stock price has experienced an abnormal fluctuation, with a cumulative increase of 20% over three consecutive trading days, indicating unusual trading activity [1] Group 1: Company Operations - The company confirmed that its production and operational activities are normal, with no significant changes in its main business, which includes IT system solutions, digital infrastructure, and digital applications [1] - There have been no major adjustments in the market environment, and production costs and sales conditions have not experienced significant fluctuations [1] - The internal production and operational order of the company remains normal [1] Group 2: Disclosure of Information - The company stated that there are no significant matters affecting the abnormal fluctuation of its stock trading, and it does not have any undisclosed major information [1] - This includes the absence of significant events such as major asset restructuring, issuance of shares, acquisitions, debt restructuring, business restructuring, asset divestiture, and asset injection [1]

Trading Information Summary - On August 15, 2025, Sino Medical (688108) closed at 34.57 CNY, up 13.72%, with a turnover rate of 17.2% and a trading volume of 715,600 lots, amounting to a total transaction value of 2.331 billion CNY [1] - The net inflow of main funds was 98.2166 million CNY, accounting for 4.21% of the total transaction value, while retail investors had a net outflow of 1.05 billion CNY, representing 4.51% of the total transaction value [1][3] Company Announcement Summary - Sino Medical's stock experienced a cumulative price deviation of 200% over 30 consecutive trading days, indicating severe abnormal trading fluctuations [1][3] - The company announced several significant updates: on July 22, a new drug-eluting stent system received conditional approval from the FDA; on July 25, the company released its half-year performance forecast for 2025; and on August 7, a subsidiary's product received breakthrough medical device designation from the FDA [1] - The company emphasized that its daily operations are normal, and there have been no significant changes in market conditions or industry policies affecting the stock's abnormal fluctuations [1]